OCGN Ocugen Inc

Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200

Ocugen Engages Kemwell Biopharma for cGMP Manufacture of OCU200
EN
06/10/2020

Underlying

OCGNOcugen Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocugen Inc

 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen Provides Business Update with Third Quarter 2025 Financial Resu...

Ocugen Provides Business Update with Third Quarter 2025 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA) provided acceptability of a single U.S.-based trial for submission of a Marketing Authorization Application (MAA) Executed licensing agreement with Kwangdong Pharmaceutical for exclusive rights in South Korea to OCU400 Sales milestones of $1.5 million for every $15 million...

November 5, 2025 1 EN
 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Dis...

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results MALVERN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s third quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, November 5, 2025. Ocugen will issue a pre-market earnings announcement on the same day. A...

October 23, 2025 1 EN
 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen to Present at Industry and Investor Conferences in October 2025

Ocugen to Present at Industry and Investor Conferences in October 2025 MALVERN, Pa., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that executive leadership will present at the 2025 Cell & Gene Meeting on the Mesa, Chardan’s 9th Annual Genetic Medicines Conference, and the 2025 Maxim Growth Summit. “These industry and investor meetings provide an excellent forum to share specifically how Ocugen is advancing toward our goal of three BLAs in the next thre...

October 2, 2025 1 EN
 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License A...

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today executed a l...

September 15, 2025 1 EN
 PRESS RELEASE
Free
OCGN OCUGEN INC

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment...

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025 MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen will participate in both a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference, September 8-10, 2025 in New York, NY and a spotlight panel titled “The FDA Gauntlet: Strategies for ...

September 2, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch